Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsAlexander Cumbo - ...

India faces rising severe obesity. Experts discuss how GLP-1 and dual GIP/GLP-1 medications, combined with lifestyle and ...

"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical data highlighting its potential to deliver durable, long-term functional ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Detailed price information for Alaunos Therapeutics Inc (TCRT-Q) from The Globe and Mail including charting and trades.

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment. For oncology clinicians, the Liver Imaging-Reporting and Data System ...

CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...

Preview the Houston Rockets' NBA matchup with the Nuggets, including betting odds, tips, trends, and game information.

Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

Non-alcoholic fatty liver disease (NAFLD) impacts millions globally, often advancing silently while elevating the challenge of metabolic disorders. While medications can aid in controlling some health ...